Form 8-K

8-K — Health In Tech, Inc.

Accession: 0001213900-26-089164

Filed: 2026-08-13

Period: 2026-08-13

CIK: 0002019505

SIC: 6411 (INSURANCE AGENTS BROKERS & SERVICES)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0301980-8k_health.htm (Primary)

EX-99.1 — PRESS RELEASE DATED AUGUST 13, 2026 (ea030198001ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0301980-8k_health.htm · Sequence: 1

false

0002019505

2026-08-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 OR 15(d) of The Securities

Exchange Act of 1934

August 13, 2026

Date of Report (Date of earliest event reported)

Health In Tech, Inc.

(Exact name of registrant as specified in its charter)

Nevada

001-42449

87-3545722

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

701 S. Colorado Ave, Suite 1

Stuart, FL

34994

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (888) 373-0333

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, $0.001 par value per share

HIT

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities

Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial

Condition.

On August 13, 2026, Health

In Tech, Inc., a Nevada corporation (the “Company”) issued a press release announcing its results of operations for the quarter

ended June 30, 2026, attached hereto as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

As disclosed in Item 2.02

above, on August 13, 2026, the Company issued a press release announcing its results of operations for the quarter ended June 30, 2026,

attached hereto as Exhibit 99.1. The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit

99.1 are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information

set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference

into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in

such filing.

Forward-Looking Statements

Certain statements in this

Current Report on Form 8-K or in the accompanying exhibits are forward-looking statements for purposes of the safe harbor provisions under

the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health

In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive

position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms

such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,”

“expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,”

“believe,” “continue,” “predict,” “project,” “potential,” “goal,”

or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s

future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s

actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance

or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements

because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s

control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Some of the risks and

uncertainties, although not all risks and uncertainties, that could cause the Company’s actual results to differ materially from

those presented in its forward-looking statements are set forth in the “Risk Factors” section in the Company’s Annual

Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission,

as such risks, uncertainties and other important factors may be updated from time to time in the Company’s subsequent reports. Any

forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other

risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

Health In Tech undertakes no obligation to update any forward-looking statements, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.

Description

99.1

Press release dated August 13, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 13, 2026

HEALTH IN TECH, INC.

By:

/s/ Tim Johnson

Name:

Tim Johnson

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE DATED AUGUST 13, 2026

EX-99.1

Filename: ea030198001ex99-1.htm · Sequence: 2

Exhibit 99.1

Health

In Tech Reports Second Quarter 2026 Financial Results

Contracted

Revenue of $32.3 Million as of June 30, 2026

Pipeline

Revenue of $66.3 Million as of July 31, 2026

Distribution

Partners Grew 19.9% Year Over Year

Stuart,

FL., August 13, 2026 /PRNewswire/ — Health In Tech, Inc. (Nasdaq: HIT) (“Health In Tech” or the “Company”),

an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three and six months ended June 30,

2026.

Second

Quarter and First-Half 2026 Highlights

● Distribution

Partners, including brokers, third-party administrators (“TPAs”) and agencies, reached 933 as of June 30, 2026, an increase

of 19.9% year over year.

● Q2

2026 Revenue was $8.1 million, compared with $9.3 million in Q2 2025. First-half 2026 revenue was $16.8 million, compared with $17.3

million in the prior year period.

● Contracted

Revenue1 totaled $32.3 million for first-half 2026, of which $17.3 million was recognized as GAAP revenue in first-half

2026. The remaining $14.0 million and $1.0 million are expected to be recognized as GAAP revenue in second-half 2026 and in 2027, respectively.

● Pipeline

Revenue2 was $66.3 million as of July 31, 2026, of which $1.9 million was contracted subsequent to quarter end. The remaining

$64.4 million represents policies in quoting or binding status, with an expected conversion rate of 15% to 40%.

● Net

loss for Q2 2026 was $2.5 million, or $(0.04) per diluted share, compared to net income of $0.6 million, or $0.01 per diluted share,

in Q2 2025, and $4.1 million for the first half of 2026, or $(0.07) per diluted share, compared to net income of $1.1 million, or $0.02

per diluted share, in first-half 2025.

● Adjusted

EBITDA3 was $(1.3) million for Q2 2026 and $(2.6) million for first-half 2026, reflecting continued investment in distribution,

technology, and product development.

● Platform

Placed Plan Value (“PPPV”)4 was $84.0 million as of June 30, 2026.

2026

Outlook and Beyond

of July 31, 2026, the Company had approximately $66.3 million in Pipeline Revenue, of which $1.9 million was contracted, while the remaining

$64.4 million is in the quoting or binding stage. Based on the Company’s estimated conversion rate of 15% to 40%, the Pipeline

Revenue in the quoting or binding stage is expected to generate approximately $9.7 million to $25.8 million of additional Contracted

Revenue. Under U.S. GAAP revenue recognition, this is expected to result in approximately $3.1 million to $8.3 million of GAAP revenue

recognized in 2026, with an additional $6.6 million to $17.5 million of GAAP revenue expected to be recognized in 2027.

With

five more months remaining in 2026, the Company expects to continue expanding its Pipeline Revenue through new product launches and new

system enhancement. Supported by its growing base of Contracted Revenue, increasing forward revenue visibility, and continued pipeline

development, the Company is reaffirming its full-year 2026 revenue guidance of $45 million to $50 million.

CEO

Commentary

Tim

Johnson, Chief Executive Officer of Health In Tech, commented, “We continued to execute against our long-term growth strategy during

the quarter by investing in sales, marketing, and key talent, supported in part by the capital raised through our recent PIPE financing.

These investments are designed to expand our distribution network, accelerate product innovation, and strengthen our execution capabilities.

Our contracted book of business continued to grow, providing greater visibility into future revenue. We believe Contracted Revenue and

Pipeline Revenue are meaningful operating metrics that complement our GAAP financial results by illustrating the strength of our sales

pipeline, the pace of customer conversion, and our expected revenue trajectory.”

Mr.

Johnson continued, “We also made meaningful progress on several strategic initiatives that we believe position the Company for

its next phase of growth. During the quarter, we contractually secured our first employer group for the Three-Year Rate Stabilization

Program, a differentiated solution designed to provide employers with greater predictability in stop-loss pricing over a multi-year period.

This represents an important milestone as we advance toward the program’s anticipated launch in the capital markets. In parallel,

we are engaged with several high-profile governmental organizations that are evaluating participation in the program, and we expect to

provide additional updates in the coming months.

we execute on our strategic roadmap, we remain on track to launch HitRix, our next-generation marketplace platform, in the second

half of 2026. While our current eDIYBS platform has transformed AI-enabled underwriting through bindable stop-loss quoting and customized

plan design, HitRix expands the application of AI across the entire self-funded stop-loss insurance ecosystem. The platform leverages

advanced AI-powered document intelligence to automate data extraction across multiple document types, enable intelligent plan comparisons,

and facilitate an integrated competitive bidding process within a unified digital marketplace. By connecting a broad network of brokers,

carriers, TPAs, and employer groups, HitRix is designed to increase market transparency, expand access to competitive stop-loss solutions,

streamline the placement process, and deliver better outcomes for all participants across the self-funded insurance value chain.”

End

Notes

1. Contracted

Revenue represents the total revenue expected to be generated over the contractual term of

self-funded health plan policies placed through the Company’s platform. Standard self-funded

plan policies generally have a contractual term of 12 months, while the Company’s

Three-Year Rate Stabilization Program is designed with a 36-month contractual

term. Revenue is recognized under U.S. GAAP on a straight-line basis over the policy term,

beginning on the policy’s effective date. Accordingly, Contracted Revenue represents

revenue that has been contractually secured but has not yet been fully recognized under U.S.

GAAP, providing an indication of future revenue expected from existing contracts.

2. Pipeline

Revenue represents revenue from self-funded plan policies that are being quoted, are in binding

status, or have been contracted subsequent to the end of the reporting period. This metric

reflects the entire contractual term of the underlying policies, some of which may not ultimately

convert to revenue.

3. Adjusted

EBITDA is a non-GAAP financial measure. Additional information and reconciliation of Adjusted

EBITDA to its most comparable GAAP financial measure is provided in the “Reconciliation

of Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA” section

of this release.

4. Platform

Placed Plan Value (“PPPV”) represents the aggregate contractual value of self-funded

health plans with stop-loss insurance (self-funded stop-loss plans) placed through the Company’s

platform during the fiscal year through the applicable fiscal quarter end, measured over

each plan’s full contractual term of typically 12 or 36 months from the plan’s

effective date. PPPV reflects the total economic value flowing through the platform, including

premium, claim funding, and administrative fees, and is a measure of platform transaction

volume rather than an indication of the Company’s own revenue or take rate.

Conference

Call Details

Health

In Tech will host a conference call to discuss its financial results for the second quarter of 2026 on August 13, 2026, at 5:00 p.m.

(ET). To participate in our live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).

live audio webcast will be available via the Investor Relations page of Health In Tech’s website at https://healthintech.com/.

A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and

will remain available for approximately 90 days.

Non-GAAP

Financial Information

This

release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance

with accounting principles generally accepted in the United States of America (“GAAP”). Management uses Adjusted EBITDA to

provide investors with additional insight into operational performance and to facilitate comparison with other companies in the industry.

Adjusted EBITDA should not be considered an alternative to net income, operating income, or other GAAP measures. A reconciliation of

historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables

found at the end of this release.

Use

of Forward-Looking Statements

Certain

statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities

Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible

or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry

environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,”

“will,” “should,” “design,” “target,” “aim,” “hope,” “expect,”

“could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,”

“continue,” “predict,” “project,” “potential,” “goal,” or other words that

convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial

performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results,

levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements

expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they

involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and

which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects

Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions

relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

About

Health In Tech

Health

In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health

insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline

the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriter (“MGUs”)

and third-party administrators (“TPAs”). Health In Tech’s platform serves as a marketplace for brokers, TPAs, MGUs

and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans,

bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.

Health

In Tech, Inc.

Consolidated

Statements of Operations

(Unaudited)

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Revenues

Revenues from underwriting modeling (ICE)

$ 1,272,647

$ 2,090,576

$ 2,741,461

$ 4,442,560

Revenues from fees (SMR)

6,783,973

7,223,273

14,086,805

12,886,273

Total revenues

8,056,620

9,313,849

16,828,266

17,328,833

Cost of revenues

4,134,127

3,003,979

8,396,374

5,663,564

Gross profit

3,922,493

6,309,870

8,431,892

11,665,269

Operating expenses

Sales and marketing expenses

2,215,889

1,226,738

4,507,490

2,316,993

General and administrative expenses

4,269,094

3,775,453

7,724,652

7,022,218

Research and development expenses

875,811

582,609

1,796,206

1,120,330

Total operating expenses

7,360,794

5,584,800

14,028,348

10,459,541

Other income (expense):

Interest income

69,568

108,198

137,039

193,564

Other income

100,000

—

122,334

118,399

Other expense

(52,341 )

—

(52,341 )

—

Total other income, net

117,227

108,198

207,032

311,963

(Loss) income before income tax expense

(3,321,074 )

833,268

(5,389,424 )

1,517,691

Income tax benefit (expense)

809,888

(202,637 )

1,289,957

(388,468 )

Net (loss) income

(2,511,186 )

630,631

(4,099,467 )

1,129,223

Net loss attributable to noncontrolling interests

(162 )

—

(162 )

—

Net (loss) income attributable to common stockholders

$ (2,511,024 )

$ 630,631

$ (4,099,305 )

$ 1,129,223

Net (loss) income per share

Basic

$ (0.04 )

$ 0.01

$ (0.07 )

$ 0.02

Diluted

$ (0.04 )

$ 0.01

$ (0.07 )

$ 0.02

Weighted average common shares outstanding:

Basic

62,829,725

55,382,395

60,106,502

55,003,233

Diluted

62,829,725

55,632,357

60,106,502

57,004,070

Reconciliation

of Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA

(Unaudited)

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Net (loss) income attributable to common stockholders

$ (2,511,024 )

$ 630,631

$ (4,099,305 )

$ 1,129,223

Interest income

(69,568 )

(108,198 )

(137,039 )

(193,564 )

Amortization expense

320,320

135,983

723,787

271,966

Income tax (benefit) expense

(809,888 )

202,637

(1,289,957 )

388,468

Stock-based compensation expense, including employer payroll taxes related to stock-based awards

959,969

707,963

1,403,808

1,201,134

Provision for credit losses on other receivables

739,773

—

739,773

—

Other non-recurring items

37,341

—

37,341

—

Total net adjustments

1,177,947

938,385

1,477,713

1,668,004

Adjusted EBITDA

$ (1,333,077 )

$ 1,569,016

$ (2,621,592 )

$ 2,797,227

Consolidated

Balance Sheets

(Unaudited)

June 30,

December 31,

2026

2025

Assets

Current assets

Cash and cash equivalents

$ 6,514,813

$ 7,669,754

Accounts receivable, net

8,546,307

756,288

Loans receivable, net

847,993

815,995

Other receivables, net

3,392,082

3,467,814

Deferred offering costs

102,586

170,977

Prepaid expenses and other current assets

2,380,284

3,280,148

Total current assets

21,784,065

16,160,976

Non-current assets

Software

7,197,718

6,530,894

Operating lease - right-of-use assets

104,277

139,940

Long-term prepaid expenses

8,184

258,151

Deferred tax assets, net

540,436

—

Total non-current assets

7,850,615

6,928,985

Total assets

$ 29,634,680

$ 23,089,961

Liabilities and stockholders’ equity

Current liabilities

Accounts payable and accrued expenses

$ 9,907,370

$ 4,188,811

Operating lease liabilities - current

81,225

76,195

Other current liabilities

—

891,598

Total current liabilities

9,988,595

5,156,604

Non-current liabilities

Deferred tax liabilities

—

757,675

Operating lease liabilities - non-current

21,713

63,617

Total non-current liabilities

21,713

821,292

Total liabilities

10,010,308

5,977,896

Stockholders’ equity

Common stock, $0.001 par value; Class A Common stock 150,000,000 shares authorized 53,858,083 and 46,006,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively

$ 53,858

$ 46,006

Common stock, $0.001 par value; Class B Common stock 50,000,000 shares authorized, 11,700,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively

11,700

Additional paid-in capital

18,365,473

11,834,121

Retained earnings

1,120,933

5,220,238

Noncontrolling interests

72,408

—

Total stockholders’ equity

19,624,372

17,112,065

Total liabilities and stockholders’ equity

$ 29,634,680

$ 23,089,961

Consolidated

Statements of Cash Flows

(Unaudited)

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Cash flows (used in) provided by operating activities:

Net (loss) income

$ (2,511,186 )

$ 630,631

$ (4,099,467 )

$ 1,129,223

Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:

Bad debt (recovery) expense

(2,954 )

5,990

(2,954 )

5,990

Amortization expense

320,320

135,983

723,787

271,966

Provision for refund liability

—

175,698

108,402

955,743

Provision for credit losses on other receivables

739,773

—

739,773

—

Deferred tax benefit

(813,639 )

(32,074 )

(1,298,111 )

(66,547 )

Interest income

(15,999 )

(31,998 )

Stock-based compensation expense

959,320

707,963

1,325,882

1,201,134

Changes in operating assets and liabilities:

Accounts receivable

(4,805,705 )

823,480

(7,787,065 )

359,982

Other receivables

(59,704 )

134,954

(71,444 )

(3,354,582 )

Prepaid expenses and other assets

350,442

455,844

798,039

(561,907 )

Operating lease right-of-use assets and liabilities, net

(606 )

(1,211 )

Accounts payable and accrued expenses

2,927,618

(1,150,600 )

4,364,800

2,269,897

Income taxes payable

—

(390,612 )

—

(170,309 )

Other current liabilities

—

(1,000,000 )

—

Net cash (used in) provided by operating activities

(2,912,320 )

1,481,276

(6,231,567 )

2,008,629

Cash flows used in investing activities:

Development of software

(596,992 )

(909,897 )

(959,123 )

(1,613,372 )

Net cash used in investing activities

(596,992 )

(909,897 )

(959,123 )

(1,613,372 )

Cash flows (used in) provided by financing activities:

Proceeds from issuance of common stock in connection with private investment in public equity financing, net of placement agent fees and escrow agent fees

—

6,381,000

—

Payments of deferred offering costs

(199,440 )

(8,250 )

(243,608 )

(106,339 )

Contributions from noncontrolling interests

71,428

—

71,428

—

Taxes paid related to net share settlement of equity awards

(173,071 )

—

(173,071 )

—

Net cash (used in) provided by financing activities

(301,083 )

(8,250 )

6,035,749

(106,339 )

(Decrease) increase in cash and cash equivalents

(3,810,395 )

563,129

(1,154,941 )

288,918

Cash and cash equivalents, beginning of the period

10,325,208

7,575,037

7,669,754

7,849,248

Cash and cash equivalents, end of the period

$ 6,514,813

$ 8,138,166

$ 6,514,813

$ 8,138,166

Supplemental disclosures of cash flow information:

Cash paid for interest

$ —

Cash paid for income taxes

$ 15,000

$ 625,323

$ 10,035

$ 625,323

Summary of noncash investing and financing activities:

Accrued deferred offering costs included in accounts payable and accrued expenses

$ 115,911

$ —

$ 215,911

$ —

Accrued development of software included in accounts payable and accrued expenses

430,386

265,243

430,386

265,243

Reclassification of deferred offering costs to additional paid-in capital upon private investment in public equity financing

75,030

—

527,910

—

Stock-based compensation capitalized for software development

10,617

—

19,454

—

Investor

Contact:

Health

In Tech Investor Relations

ir@healthintech.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 13, 2026

Entity File Number

001-42449

Entity Registrant Name

Health In Tech, Inc.

Entity Central Index Key

0002019505

Entity Tax Identification Number

87-3545722

Entity Incorporation, State or Country Code

Entity Address, Address Line One

701 S. Colorado Ave

Entity Address, Address Line Two

Suite 1

Entity Address, City or Town

Stuart

Entity Address, State or Province

Entity Address, Postal Zip Code

34994

City Area Code

888

Local Phone Number

373-0333

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A Common Stock, $0.001 par value per share

Trading Symbol

HIT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration